Level of Serum Adiponectin in Sjögren’s Syndrome

Amaç & Hipotez:Objective: To evaluate the serum adiponectin level and determine the association between adiponectin and various clinical and laboratory findings in patients with primary Sjögren’s syndrome (pSS).

📊

Temel Bulgular & Veri:Materials and Methods: A total of 50 patients and 30 healthy volunteers were enrolled in the present study.

💡

Sonuç & Katkı:Conclusion: These findings indicate that adiponectin does not play a crucial role in the immunological and clinical patterns of pSS.

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Özet

Objective: To evaluate the serum adiponectin level and determine the association between adiponectin and various clinical and laboratory findings in patients with primary Sjögren’s syndrome (pSS). Materials and Methods: A total of 50 patients and 30 healthy volunteers were enrolled in the present study. Serum adiponectin levels were detected by colorimetric enzyme-linked immunosorbent assay. The medical history of patients including complete blood count analysis; high sensitive C-reactive protein; erythrocyte sedimentation rate (ESR); complement component 3; complement component 4; low density lipoprotein cholesterol; triglyceride; immunoglobulin G (IgG), IgA, and IgM levels; and the status of Ro 60, Ro 52, Sjögren’s syndrome A, Sjögren’s syndrome B, and rheumatoid factor were obtained from laboratory information system. Results: Serum adiponectin levels were 2.34 (0.77–4.95) ng/mL and 1.73 (0.01–7.76) ng/mL in patients and controls, respectively (p=0.316). Positive correlation was observed between the values of serum adiponectin, ESR (p=0.013, rho=0.362), and body mass index (p=0.018, rho=0.362) in patients. Conclusion: These findings indicate that adiponectin does not play a crucial role in the immunological and clinical patterns of pSS.

🔖

Bu Makaleye Atıf Yap

DOĞAN, K., URHAN, M. E., YILDIZ, Ş., DERİN, E., ŞAHİN, A., DOĞAN, H. O. (2019). Level of Serum Adiponectin in Sjögren’s Syndrome. Erciyes Medical Journal, Cilt: 41 - Sayı: 2, 186–190. https://ajindex.com/articles/189644

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11(8):327–32. [CrossRef] Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007;3(12):716–24. [CrossRef] Fantuzzi G. Adiponectin in inflammatory and immune-mediated diseases. Cytokine 2013;64(1):1–10. [CrossRef] Riis JL, Bryce CI, Ha T, Hand T, Stebbins JL, Matin M, et al. Adiponectin: Serum-saliva associations and relations with oral and systemic markers of inflammation. Peptides 2017;91:58–64. [CrossRef] Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, et al. Plasma adiponectin in patients with active, early, and chronicrheumatoid arthritis who are steroid- and disease-modifyingantirheumatic drug-naive compared with patients with osteoarthritisand controls. J Rheumatol 2009;36(9):1885–91. [CrossRef] Filková M, Lisková M, Hulejová H, Haluzík M, Gatterová J, Pavelková A, et al. Increased serum adiponectin levels in female patients with erosivecompared with non-erosive osteoarthritis. Ann Rheum Dis 2009;68(2):295–6. [CrossRef] Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(9):1198–201. [CrossRef] Goules AV, Tzioufas AG. Primary Sjögren’s syndrome: clinical phenotypes, outcome and the development of biomarkers. Immunol Res 2017;65(1):331–44. [CrossRef] Nocturne G, Mariette X. Advances in understanding the pathogenesis of primarySjögren’s syndrome. Nat Rev Rheumatol 2013;9(9):544–56.
Mavragani CP, Moutsopoulos HM. Sjögren’s syndrome. Annu Rev Pathol 2014;9:273–85. [CrossRef] Maślińska M, Przygodzka M, Kwiatkowska B, Sikorska-Siudek K. Sjögren’s syndrome: still not fully understood disease. Rheumatol Int 2015;35(2):233–41. [CrossRef] Abella V, Scotece M, Conde J, López V, Lazzaro V, Pino J, et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res 2014;2014:343746. [CrossRef] Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM,et al. 2016 American College of Rheumatology/European LeagueAgainst Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology InvolvingThree International Patient Cohorts. Arthritis Rheumatol 2017;69(1):35–45. [CrossRef] Mariette X, Criswell LA. Primary Sjögren’s Syndrome. N Engl J Med